| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802884302069 | 288430206 | VALSARTAN/SANDOZ F.C.TAB 80MG/TAB (Γενοσημου) BT x 28 | 3.25 | 3.41 | 4.70 |
| 05/2018 | 2802884303066 | 288430306 | VALSARTAN/SANDOZ F.C.TAB 160MG/TAB (Γενοσημου) BT x 28 | 4.00 | 4.20 | 5.79 |
| 05/2018 | 2802884304063 | 288430406 | VALSARTAN/SANDOZ F.C.TAB 320MG/TAB (Γενοσημου) BT x 28 | 6.23 | 6.53 | 9.00 |
For the treatment of hypertension.
Valsartan competes with angiotensin II for binding at the AT<sub>1</sub> receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
Absolute bioavailability = 23% with high variability
The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.
* 17 L
* 2 L/h [IV administration] * 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]